Phosphoproteomics identifies determinants of PAK inhibitor sensitivity in leukaemia cells
In summary, our data define the proteomic, molecular and functional responses of primary and immortalised AML cells to PF-3758309 and suggest a route to personalise AML treatments based on PAK inhibitors.
Authors
- Santiago Marfà (ORCID: https://orcid.org/0000-0002-5862-9560)
- Marwa Mohammed Hadi (ORCID: https://orcid.org/0000-0003-4819-6017)
- Pedro R. Cutillas (ORCID: https://orcid.org/0000-0002-3426-2274)
- Vinothini Rajeeve (ORCID: https://orcid.org/0000-0002-6361-4291)
- Sandra M. Martín‐Guerrero (ORCID: https://orcid.org/0000-0003-1489-4757)
- Farideh Miraki‐Moud
- Pedro Casado (ORCID: https://orcid.org/0000-0002-4207-9349)
- Henry Gerdes
Institutions
- Queen Mary University of London (GB)
Publication Details
- Journal
- Cell Communication and Signaling
- Published
- 2025-03-13
- DOI
- https://doi.org/10.1186/s12964-025-02107-0
- Citations
- 5
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 8.85
Funders
- Cancer Research UK
- Blood Cancer UK